BioMarin Completes Amicus Acquisition, Expands Rare Disease Portfolio

BioMarin Pharmaceutical ( (BMRN) ) just unveiled an update.

On April 27, 2026, BioMarin completed its previously announced all-cash acquisition of Amicus Therapeutics for $14.50 per share, valuing the target at about $4.8 billion and converting all eligible Amicus equity and equity-based awards into cash. The transaction, financed through a mix of new senior secured credit facilities totaling $3.4 billion, previously issued 5.500% senior notes due 2034 and cash on hand, also triggered the termination of BioMarin’s prior credit agreement and the extension of guarantees on its 2034 notes by additional subsidiaries.

The deal immediately adds three key assets to BioMarin’s rare disease franchise: Galafold, the first oral therapy for Fabry disease approved in more than 40 countries, the Pompe disease combination therapy Pombiliti plus Opfolda and U.S. rights to Phase 3 candidate DMX-200 for focal segmental glomerulosclerosis. By broadening its portfolio of lysosomal storage disease treatments and late-stage pipeline, while locking in substantial but covenant-heavy, asset-backed financing, BioMarin enhances its scale and diversification in the rare disease market, with implications for stronger revenue growth and expanded reach to specialized patient populations.

BioMarin Expects to Provide Updated FY 2026 Guidance During its First Quarter Earnings Call, May 4, 2026. The completion of the Amicus acquisition advances BioMarin’s strategy to strengthen and diversify its growth profile while furthering its mission to deliver medicines for people living with rare diseases.

The most recent analyst rating on (BMRN) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

Spark’s Take on BMRN Stock

According to Spark, TipRanks’ AI Analyst, BMRN is a Neutral.

The score is driven primarily by solid fundamentals (growth, high gross margins, strong balance sheet, and healthy cash generation) and a largely positive outlook/guidance from the latest earnings call. Offsetting factors are weak technical momentum (below key moving averages with negative MACD), a premium P/E without dividend support, and mixed event risk from the VOXZOGO trial halt and leverage tied to the Amicus acquisition.

To see Spark’s full report on BMRN stock, click here.

More about BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a global biotechnology company focused on rare, genetically defined diseases, with a portfolio of commercial therapies targeting lysosomal storage disorders and other inherited conditions, as well as a robust clinical and preclinical pipeline. Founded in 1997 and based in San Rafael, California, the company leverages in-house manufacturing and worldwide commercial infrastructure to develop and distribute category-defining medicines.

BioMarin’s strategy centers on using genetic science to address high unmet medical needs in small patient populations, positioning the company as a specialist in niche, high-value therapies. Its established presence in key markets such as the U.S., EU, U.K., and Japan supports its expansion into additional rare disease segments and enhances its ability to integrate acquired assets into its existing commercial and operational platform.

Average Trading Volume: 2,017,663

Technical Sentiment Signal: Strong Sell

Current Market Cap: $10.23B

Find detailed analytics on BMRN stock on TipRanks’ Stock Analysis page.